The company is seeking approval for narsoplimab as a potential treatment for a fatal disease called hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Omeros said it has also requested for a type A meeting with the FDA to resolve any outstanding items.
Price: 5.19, Change: +0.03, Percent Change: +0.58
|Decibel Therapeutics Says Topline Trial Shows DB-020...|
|Stifel Adjusts Nike's Price Target to $135 From $150...|
|Market Chatter: Uber, Transport Workers Union in Aus...|
|Cognyte Software Swings to Fiscal Q1 Adjusted Loss; ...|
|JMP Securities Adjusts Price Target on Karuna Therap...|